Adverse Event reporting and Prescribing Information can be found via the links above

ANDEMBRY garadacimab 200mg

ANDEMBRY® OFFERS HAE
PATIENTS CONVENIENT AND
CONSISTENT DOSING1

ANDEMBRY® OFFERS
HAE PATIENTS
CONVENIENT AND
CONSISTENT DOSING1

ANDEMBRY® (garadacimab) is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.1

The person represented in this material is not an actual patient.

Low volume subcutaneous injection (200 mg/1.2 mL) administered once per month – after initial loading dose of 400 mg (2 x 200 mg) on first day of treatment1

Long shelf life of three years – when stored in the carton in the refrigerator (2–8°C), away from light1

Storing is flexible to fit into patients’ lives – ANDEMBRY® should be stored in the refrigerator; it can be stored at room temperature (up to 25°C) for a single period of up to 2 months, but not beyond expiry. After storing at room temperature, do not return to refrigerator1

*Please refer to the Summary of Product Characteristics (SmPC) for full information before prescribing.

Self-inject in up to 15 seconds† – injection sites should be rotated regularly, between the upper outer arm, the abdomen, and the thigh

Image of Andembry pen

†May not apply to all patients treated with ANDEMBRY®.
ANDEMBRY® should only be administered by the patient or their caregiver after appropriate training by a qualified healthcare professional.1

*Please refer to the Summary of Product Characteristics (SmPC) for full information before prescribing.

Explore more

Learn how ANDEMBRY® is changing the path in HAE
Explore reduced HAE attacks with ANDEMBRY® (VANGUARD)
Discover the latest insights on ANDEMBRY®

Abbreviations: HAE, hereditary angioedema; OLE, open-label extension; nC1-INH HAE, HAE with normal functioning C1-INH; SmPC, Summary of Product Characteristics.

References:
1. ANDEMBRY® (garadacimab). Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple store. Adverse events should also be reported to CSL Behring UK Ltd. on 01444 447405.

GBR-AND-0216 | May 2026.